The First Potential Therapy for Congenital Adrenal Hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare endocrine disorder that results in the inability to produce the critical ‘stress’ hormone cortisol. Although CAH testing is a part of the newborn screening program, there are currently no FDA-approved therapies for CAH. CAH is typically treated with chronic, high-dose steroids often resulting in significant side effects.

Spruce’s lead product candidate for CAH, SPR001, is intended to correct hormone imbalance, giving patients a therapeutic option that treats their underlying disease and reduces their steroid burden.

Learn About CAH + View Our Research Pipeline +

Now Enrolling Patients for

Congenital Adrenal Hyperplasia Clinical Trials 2018

If you are an adult with a genetic diagnosis of classic Congenital Adrenal Hyperplasia, you may be eligible to participate in a Phase 2 clinical trial for a new therapy for CAH. To be notified when a site opens near you, sign up for our mailing list.

Our Phase 2 program has active sites in San Diego, CA, Orange, CA, Las Vegas, NV, Atlanta, GA, Indianapolis, IN, Minneapolis, MN, Melbourne, FL, Philadelphia, PA.

Learn More